Please ensure Javascript is enabled for purposes of website accessibility

Ionis Receives Orphan Drug Designation From EMA

By Taylor Carmichael - Feb 11, 2020 at 10:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is advancing a new treatment for people with Alexander disease.

Ionis Pharmaceuticals (IONS -1.08%) announced Tuesday that ION373, a treatment for people with Alexander disease, has received an "orphan drug" designation from the European Medicines Agency (EMA). Alexander disease is a rare genetic disease characterized by abnormal protein deposits (also known as Rosenthal fibers) in the body and the destruction of the myelin sheaths (the fatty coverings that insulate nerve fibers). Its symptoms in children include an enlarged brain and head, seizures, mental retardation, and delayed physical development. Alexander disease is often fatal. 

Drug development is an expensive process, but many crippling and life-threatening conditions affect such small patient populations that there's no way to find effective treatments for them profitably without government aid. To provide that assistance, governments give the drugs that treat those "orphan diseases" an easier pathway to regulatory approval, and longer patent exclusivity periods, among other benefits.

The number of people who suffer from Alexander disease is unknown, but about 500 people have been diagnosed with the disorder since it was discovered in 1949.  

DNA strand

Image source: Getty Images

"We look forward to working closely with European regulators, clinical investigators, Alexander disease patients and their families to advance this important medicine and make it available to those who need it," said Ionis CEO Brett P. Monia. "Receiving orphan drug status reflects the urgent need for ION373, which is among a number of wholly owned, novel drugs in the Ionis pipeline that we are prioritizing." 

Ionis specializes in antisense therapy, a type of gene therapy that involves synthesizing a strand of nucleic acid that will bind to the messenger RNA (mRNA) produced by the faulty gene and shut it off. Ionis has had antisense drugs approved for spinal muscular atrophy (SMA) and hATTR amyloidosis, a disease that affects peripheral nerves. The company has over 40 molecules in its pipeline, including 28 drugs that are currently in clinical trials.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$37.56 (-1.08%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.